The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)Mark Hudson, Richard Aspinall, W.J. Cash et al.|Frontline Gastroenterology|2017Cited by 28
Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)Richard Aspinall, Debbie L. Shawcross, Mark Hudson et al.|Frontline Gastroenterology|2022Cited by 5
P054 Long term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long term follow-up (IMPRESS II)Mark Hudson, Richard Aspinall, Joe Hickey et al.|Unknown|2021Cited by 0